Literature DB >> 14644040

Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders.

Markus Reindl1, Sabrina Khantane, Rainer Ehling, Kathrin Schanda, Andreas Lutterotti, Claudia Brinkhoff, Thomas Oertle, Martin E Schwab, Florian Deisenhammer, Thomas Berger, Christine E Bandtlow.   

Abstract

Nogo-A is a protein associated with central nervous system (CNS) myelin thought to impair regenerative responses and to suppress sprouting and plastic changes of synaptic terminals. In this study, we report that serum IgM autoantibodies to the recombinant large N-terminal inhibitory domain of Nogo-A are a frequent finding in multiple sclerosis (MS) and acute inflammatory (IND) and non-inflammatory neurological diseases (OND), but not in neurodegenerative diseases (ND), systemic inflammatory disease and healthy controls. Furthermore, we demonstrate intrathecal production of anti-Nogo-A antibodies measured by increased IgG indices. Intrathecal anti-Nogo antibodies were significantly more frequent in patients with relapsing-remitting as compared to chronic progressive (CP) MS. We also found a highly significant negative correlation of these antibody responses with age indicating that they are more frequent in younger patients. We finally demonstrate that human anti-Nogo-A antibodies recognize native Nogo-A in brain extracts, oligodendrocytes and cells expressing human Nogo-A.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644040     DOI: 10.1016/j.jneuroim.2003.09.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Nogo-A marks motor neuron disease.

Authors:  Noam Y Harel; Stephen M Strittmatter
Journal:  Ann Neurol       Date:  2007-07       Impact factor: 10.422

Review 2.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

Authors:  Panos Stathopoulos; Harry Alexopoulos; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

Review 3.  Nogo-A Antibodies for Progressive Multiple Sclerosis.

Authors:  Benjamin V Ineichen; Patricia S Plattner; Nicolas Good; Roland Martin; Michael Linnebank; Martin E Schwab
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

Review 4.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

5.  Age-dependent decline of nogo-a protein in the mouse cerebrum.

Authors:  Anita Kumari; M K Thakur
Journal:  Cell Mol Neurobiol       Date:  2014-07-31       Impact factor: 5.046

Review 6.  The role of reticulons in neurodegenerative diseases.

Authors:  Valerio Chiurchiù; Mauro Maccarrone; Antonio Orlacchio
Journal:  Neuromolecular Med       Date:  2013-11-12       Impact factor: 3.843

Review 7.  The Implication of Reticulons (RTNs) in Neurodegenerative Diseases: From Molecular Mechanisms to Potential Diagnostic and Therapeutic Approaches.

Authors:  Agnieszka Kulczyńska-Przybik; Piotr Mroczko; Maciej Dulewicz; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

Review 8.  The reticulons: a family of proteins with diverse functions.

Authors:  Yvonne S Yang; Stephen M Strittmatter
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

9.  Antibody signatures in patients with histopathologically defined multiple sclerosis patterns.

Authors:  Lidia Stork; David Ellenberger; Klemens Ruprecht; Markus Reindl; Tim Beißbarth; Tim Friede; Tania Kümpfel; Lisa A Gerdes; Mareike Gloth; Thomas Liman; Friedemann Paul; Wolfgang Brück; Imke Metz
Journal:  Acta Neuropathol       Date:  2020-01-16       Impact factor: 17.088

10.  Correlation Between Anti-Myelin Proteolipid Protein (PLP) Antibodies and Disease Severity in Multiple Sclerosis Patients With PLP Response-Permissive HLA Types.

Authors:  Judith M Greer; Elisabeth Trifilieff; Michael P Pender
Journal:  Front Immunol       Date:  2020-08-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.